PFIZER ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 2B/3 TRIAL OF RITLECITINIB IN ALOPECIA AREATA

View source version on?businesswire.com:?https://www.businesswire.com/news/home/20210804005212/en/
Media Relations: Steve Danehy +1 (212) 733-1538 Steven.Danehy@pfizer.com? Investor Relations: Bryan Dunn +1 (212) 733-8917 Bryan.Dunn@Pfizer.com Source: Pfizer Inc.